{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:53:06Z","timestamp":1793267586437,"version":"4.5.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vaccination against high-risk HPV types is a key preventive measure. However, concerns regarding vaccine safety may hinder vaccination efforts. This study aims to evaluate adverse events (AEs) reported in the Vaccine Adverse Event Reporting System (VAERS) following HPV vaccination from 2006 to 2024, providing insights into its safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed VAERS data, a spontaneous reporting system containing de-identified AE reports. Four disproportionality analyses (ROR, PRR, BCPNN, and MGPS) were applied, and adverse event signals were defined only when the positive criteria were simultaneously met across all four methods. Statistical analyses were performed using R software and Microsoft Excel, with a significance threshold of p\u2009&lt;\u20090.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 77,909 HPV vaccine-related AE reports were analyzed, with 68.4% involving females and 48.7% affecting individuals under 18. Serious AEs accounted for 11,659 reports, with headache and fatigue being the most common. Syncope was the most frequent signal, while postural orthostatic tachycardia syndrome (POTS) exhibited the strongest signal strength. Approximately 90% of AEs occurred within 30 days post-vaccination. Among vaccine types, HPV4 had the highest number of reports, and intramuscular injection was the most common administration route.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study offers an updated pharmacovigilance assessment of adverse events reported following HPV vaccination, highlighting reported patterns and statistical signals that may warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0351652","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:26:57Z","timestamp":1781717217000},"page":"e0351652","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse events following HPV vaccine reported to the Vaccine Adverse Event Reporting System"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5065-8278","authenticated-orcid":true,"given":"Siqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"3","key":"pone.0351652.ref001","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/OLQ.0b013e318286bb53","article-title":"Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008","volume":"40","author":"CL Satterwhite","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"12","key":"pone.0351652.ref002","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"118","author":"DM Parkin","year":"2006","journal-title":"Int J Cancer"},{"issue":"2","key":"pone.0351652.ref003","article-title":"Papillomavirus infections--a major cause of human cancers","volume":"1288","author":"H zur Hausen","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"pone.0351652.ref004","article-title":"Global burden of human papillomavirus and related diseases","author":"D Forman","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"pone.0351652.ref005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-11-0542","article-title":"Reducing HPV-associated cancer globally","volume":"5","author":"DR Lowy","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"issue":"11","key":"pone.0351652.ref006","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The estimated lifetime probability of acquiring human papillomavirus in the United States","volume":"41","author":"HW Chesson","year":"2014","journal-title":"Sex Transm Dis"},{"issue":"21","key":"pone.0351652.ref007","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1002\/cncr.33795","article-title":"Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years","volume":"127","author":"S Lin","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"pone.0351652.ref008","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11912-014-0402-4","article-title":"The burden of HPV-associated anogenital cancers","volume":"16","author":"K Wakeham","year":"2014","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"pone.0351652.ref009","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"pone.0351652.ref010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"E-M de Villiers","year":"2004","journal-title":"Virology"},{"issue":"3","key":"pone.0351652.ref011","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/QAI.0000000000001113","article-title":"Effect of HIV infection on Human Papillomavirus types causing invasive cervical cancer in Africa","volume":"73","author":"GM Clifford","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"pone.0351652.ref012","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"GM Clifford","year":"2003","journal-title":"Br J Cancer"},{"key":"pone.0351652.ref013","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/1471-2407-13-553","article-title":"Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination","volume":"13","author":"JM Pimenta","year":"2013","journal-title":"BMC Cancer"},{"issue":"2","key":"pone.0351652.ref014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis","volume":"18","author":"C Lin","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pone.0351652.ref015","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/v15071440","article-title":"Recent developments in Human Papillomavirus (HPV) Vaccinology","volume":"15","author":"A-L Williamson","year":"2023","journal-title":"Viruses"},{"issue":"9518","key":"pone.0351652.ref016","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"DM Harper","year":"2006","journal-title":"Lancet"},{"issue":"43","key":"pone.0351652.ref017","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1016\/j.vaccine.2017.08.090","article-title":"Human papillomavirus vaccination coverage using two-dose or three-dose schedule criteria","volume":"35","author":"X Lin","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"pone.0351652.ref018","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/ijgc-2020-001285","article-title":"World Health Organization call for action to eliminate cervical cancer globally","volume":"30","author":"M Gultekin","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"pone.0351652.ref019","article-title":"Updates on HPV Vaccination","volume":"13","author":"O Illah","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"pone.0351652.ref020","article-title":"Investigating safety profiles of human papillomavirus vaccine across group differences using VAERS data and MedDRA","volume":"7","author":"Y Jia","year":"2019","journal-title":"PeerJ"},{"issue":"40","key":"pone.0351652.ref021","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2020.07.039","article-title":"Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra\u00ae) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016","volume":"38","author":"TR Myers","year":"2020","journal-title":"Vaccine"},{"issue":"9","key":"pone.0351652.ref022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24502","article-title":"Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States","volume":"4","author":"K Sonawane","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"36","key":"pone.0351652.ref023","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"TT Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"pone.0351652.ref024","first-page":"1178222617700627","article-title":"Analysis of individual differences in vaccine pharmacovigilance using VAERS data and MedDRA system organ classes: a use case study with trivalent influenza vaccine","volume":"9","author":"J Du","year":"2017","journal-title":"Biomed Inform Insights"},{"key":"pone.0351652.ref025","doi-asserted-by":"crossref","first-page":"20420986241226566","DOI":"10.1177\/20420986241226566","article-title":"Determinants of COVID-19 vaccine-induced myocarditis","volume":"15","author":"J Rose","year":"2024","journal-title":"Ther Adv Drug Saf"},{"issue":"10","key":"pone.0351652.ref026","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s00431-023-05146-2","article-title":"Drug-associated kidney injury in children: a disproportionality analysis of the FDA Adverse Event Reporting System","volume":"182","author":"M Zhang","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"1","key":"pone.0351652.ref027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"pone.0351652.ref028","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"pone.0351652.ref029","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"A Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"pone.0351652.ref030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"A Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"pone.0351652.ref031","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"AC Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"pone.0351652.ref032","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1791","article-title":"Safety of the 9-Valent Human Papillomavirus Vaccine","volume":"144","author":"TT Shimabukuro","year":"2019","journal-title":"Pediatrics"},{"issue":"4","key":"pone.0351652.ref033","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40264-017-0625-z","article-title":"Safety of human papillomavirus vaccines: an updated review","volume":"41","author":"A Phillips","year":"2018","journal-title":"Drug Saf"},{"issue":"4","key":"pone.0351652.ref034","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(20)30010-4","article-title":"Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study","volume":"5","author":"KT Simms","year":"2020","journal-title":"Lancet Public Health"},{"issue":"1","key":"pone.0351652.ref035","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1186\/s12889-018-6268-x","article-title":"Decline in HPV-vaccination uptake in Denmark - the association between HPV-related media coverage and HPV-vaccination","volume":"18","author":"CH Suppli","year":"2018","journal-title":"BMC Public Health"},{"issue":"9987","key":"pone.0351652.ref036","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/S0140-6736(15)61152-7","article-title":"HPV vaccination crisis in Japan","volume":"385","author":"SJB Hanley","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"pone.0351652.ref037","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.vaccine.2019.12.019","article-title":"Resilience of HPV vaccine uptake in Denmark: Decline and recovery","volume":"38","author":"PR Hansen","year":"2020","journal-title":"Vaccine"},{"issue":"21","key":"pone.0351652.ref038","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.vaccine.2016.03.087","article-title":"Can the vaccine adverse event reporting system be used to increase vaccine acceptance and trust?","volume":"34","author":"LD Scherer","year":"2016","journal-title":"Vaccine"},{"issue":"12","key":"pone.0351652.ref039","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems for vaccine adverse events","volume":"85","author":"S Rosenthal","year":"1995","journal-title":"Am J Public Health"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:27:02Z","timestamp":1781717222000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351652"}},"subtitle":[],"editor":[{"given":"Morufu Olalekan","family":"Raimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0351652","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}